Form 4 for RNA Atrium Therapeutics, Inc.
Accepted 2026-04-22 17:54:06 ET · period of report 2026-04-20 · accession 0001193125-26-170963 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-04-22 17:54 | 2026-04-20 | RNA | Hughes Steven George | Chief Medical Off | A - Grant | $0.00 | +30.0K | 73.1K | +70% | $0 |
| D | 2026-04-22 17:54 | 2026-04-20 | RNA | Hughes Steven George | Chief Medical Off | A - Grant | $0.00 | +60.0K | 60.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-20 | A | A | 30,000 | $0.00 | 73,097 | D | — | — | (F1) Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-04-20 | A | A | 60,000 | $0.00 | 60,000 | D | $14.30 · — to 2036-04-20 | 60,000 Common Stock | (F2) Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |